Literature DB >> 10100716

Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis.

P D Sturm1, E A Rauws, R H Hruban, E Caspers, T B Ramsoekh, K Huibregtse, L A Noorduyn, G J Offerhaus.   

Abstract

Extrahepatic biliary stenosis can be caused by benign and malignant disorders. In most cases, a tissue diagnosis is needed for optimal management of patients, but the sensitivity of biliary cytology for the diagnosis of a malignancy is relatively low. The additional diagnostic value of K-ras mutational analysis of endobiliary brush cytology was assessed. Endobiliary brush cytology specimens obtained during endoscopic retrograde cholangiopancreaticography were prospectively collected from 312 consecutive patients with extrahepatic biliary stenosis. The results of conventional light microscopic cytology and K-ras codon 12 mutational analysis were compared and evaluated in view of the final diagnosis made by histological examination of the stenotic lesion and/or patient follow-up. The sensitivities of cytology and mutational analysis to detect malignancy were 36 and 42%, respectively. When both tests were combined, the sensitivity increased to 62%. The specificity of cytology was 98%, and the specificity of the mutational analysis and of both tests combined was 89%. Positive predictive values for cytology, mutational analysis, and both tests combined were 98, 92, and 94%, whereas the corresponding negative predictive values were 34, 34, and 44%, respectively. The sensitivity of K-ras mutational analysis was 63% for pancreatic carcinomas compared to 27% for bile duct, gallbladder, and ampullary carcinomas. K-ras mutational analysis can be considered supplementary to conventional light microscopy of endobiliary brush cytology to diagnose patients with malignant extrahepatic biliary stenosis, particularly in the case of pancreatic cancer. The presence of a K-ras codon 12 mutation in endobiliary brush cytology per se supports a clinical suspicion of malignancy, even when the conventional cytology is negative or equivocal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100716

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Biliary brush cytology: factors associated with positive yields on biliary brush cytology.

Authors:  Nasim Mahmoudi; Robert Enns; Jack Amar; Jaber AlAli; Eric Lam; Jennifer Telford
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

2.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

3.  Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases.

Authors:  C J Stewart; P R Mills; R Carter; J O'Donohue; G Fullarton; C W Imrie; W R Murray
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

4.  Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.

Authors:  Benjamin R Kipp; Emily G Barr Fritcher; Amy C Clayton; Gregory J Gores; Lewis R Roberts; Jun Zhang; Michael J Levy; Kevin C Halling
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

5.  Early diagnosis of pancreatobiliary duct malignancies by brush cytology and biopsy.

Authors:  Gábor Elek; Tibor Gyökeres; Eszter Schäfer; Mária Burai; Ferenc Pintér; Akos Pap
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

6.  The Significance of p53 and K-ras Immunocytochemical Staining in the Diagnosis of Malignant Biliary Obstruction by Brush Cytology during ERCP.

Authors:  Young Sup Kim; Ho Gak Kim; Jimin Han; Change Jae Hur; Byeong Suk Kim; Jin Tae Jung; Joong Goo Kwon; Eun Young Kim; Chang-Ho Cho; Yoon Kyung Sohn
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

7.  Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses.

Authors:  N T van Heek; S J Clayton; P D J Sturm; J Walker; D J Gouma; L A Noorduyn; G J A Offerhaus; J C Fox
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

Review 8.  Diagnosis and treatment of cholangiocarcinoma.

Authors:  Kirsten Muri Boberg; Erik Schrumpf
Journal:  Curr Gastroenterol Rep       Date:  2004-02

9.  Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology.

Authors:  Chanjuan Shi; Arjun Chandrasekaran; Paul J Thuluvath; Collins Karikari; Pedram Argani; Michael Goggins; Anirban Maitra; James R Eshleman
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

10.  Unexpected benign histopathology after pancreatoduodenectomy for presumed malignancy: accepting the inevitable.

Authors:  Rachel M Gomes; Munita Bal; Shraddha Patkar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2016-01-26       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.